Study of the immune system modulations of melanoma patients treated with anti -PD1 monoclonal antibodies [Etude des modulations du système immunitaire des patients atteints de mélanome et traités par anticorps monoclonaux anti-PD1]

Trial Profile

Study of the immune system modulations of melanoma patients treated with anti -PD1 monoclonal antibodies [Etude des modulations du système immunitaire des patients atteints de mélanome et traités par anticorps monoclonaux anti-PD1]

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Aug 2015

At a glance

  • Drugs Ipilimumab (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 21 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top